Search for content, post, videos
Advertisement

Nykode announces expansion of oncology pipeline

Nykode Therapeutics has announced an expansion of the pipeline with a potential first-in-class preclinical oncology vaccine program aimed at preventing and treating colorectal cancer.

“The potential first-in-class program reaffirms Nykode’s vision of building a balanced cancer vaccine portfolio. We are excited about the transformative power of our next-generation technology with the potential to reduce the burden of colorectal cancer,” says Michael Engsig, CEO of Nykode.

Additionally, it signifies our belief in the promise of cancer vaccines across all stages of cancer development.”

The program will incorporate Nykode’s 4th module second-generation technology to further optimize the immune responses tailored to diverse target populations. The program builds on Nykode’s differentiating competence of creating broad and robust CD8 T cell responses with the potential to break tolerance against tumor-associated antigens, as illustrated by data presented at Nykode’s recent Capital Market Day, the company states. Preclinical data generated in the discovery phase further supports the induction of potent CD8 T cell responses in both wild-type and HLA transgenic mice models.

“I am thrilled about this exciting addition to our pipeline, which underscores Nykode’s dedication to creating innovative solutions for an expanding range of patients in need of alternative therapies,” says Mikkel W. Pedersen, Nykode’s Chief Scientific Officer. “Additionally, it signifies our belief in the promise of cancer vaccines across all stages of cancer development.”

Photo of Mikkel W. Pedersen: Nykode

Advertisement